Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2012-08-27 Director's Dealing
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2012-08-27 English
CURRENT REPORT ON FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into material definitive agreements, specifically license and distribution agreements with More Pharma Corporation. It includes details about the agreements, payment terms, and the effective date. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a significant contractual event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (8938 characters) and content confirm it is not merely a brief announcement but a full Form 8-K report, which fits under RNS as a general regulatory announcement category for filings that do not fit other specific categories.
2012-08-15 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2013
2012-08-03 English
CURRENT REPORT ON FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 2, 2012. It announces the issuance of a press release containing financial results for the fiscal quarter ended June 30, 2012. The text explicitly states that the press release is furnished as an exhibit and does not contain the financial results itself, only the announcement of those results. The document length is 4135 characters, which is relatively short and consistent with an announcement rather than a full financial report. Therefore, this document is an initial announcement of quarterly financial results, which corresponds to an Earnings Release (ER).
2012-08-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated July 27, 2012. It includes a letter to shareholders from the CEO, which will be mailed with the proxy statement and annual report. The document explicitly states it is a current report and not the annual report itself. The content is a disclosure letter and forward-looking statements, not financial statements or detailed financial data. The document is about Regulation FD Disclosure and does not contain the full annual report or proxy materials, only a letter and notice. The length is 4843 characters, which is relatively short and consistent with a current report filing. Therefore, this is a Regulatory Filing (RNS) rather than an Annual Report (10-K) or Proxy Solicitation (PSI).
2012-07-30 English
PROXY STATEMENT
Proxy Solicitation & Information Statement
2012-07-27 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.